What Science Says About Encore CBD Gummies for Wellness - Mustaf Medical

Understanding Encore CBD Gummies

Introduction

Most adults face at least one day a week when stress, restless nights, or minor joint discomfort feel unavoidable. Jane, a 38‑year‑old marketing manager, often finds herself scrolling through emails late into the evening, noticing that her muscles feel tense and her mind remains "on‑loop." She has heard about cannabidiol (CBD) gummies marketed as a convenient way to support relaxation without the need for oils or vaporizers. Curious but cautious, she wonders whether the scientific literature supports using a product like Encore CBD gummies for everyday wellness. This article reviews the current evidence, focusing on mechanisms, dosing, safety, and how gummy delivery compares with other CBD formats.

Background

Encore CBD gummies are orally administered, gelatin‑based chewables that contain a measured amount of cannabidiol extracted from the hemp plant (Cannabis sativa L.) and meet the legal definition of a "cannabidiol product" under the 2018 Farm Bill. The gummies are typically formulated with 5 mg to 25 mg of CBD per piece, along with sweeteners, flavorings, and sometimes auxiliary ingredients such as melatonin or turmeric. Unlike prescription cannabis products, these gummies are sold as dietary supplements and are not evaluated by the U.S. Food and Drug Administration (FDA) for efficacy or safety.

Research interest in oral CBD has risen sharply since 2020. A 2023 systematic review in Frontiers in Pharmacology identified 48 randomized controlled trials (RCTs) investigating oral CBD for anxiety, sleep, and pain, noting modest effect sizes and a high degree of heterogeneity across study designs. The appeal of gummies lies in their discrete dosing, palatable form, and perceived consistency compared with oils, which can vary in dropper volume and user technique.

Science and Mechanism

Pharmacokinetics of Ingested CBD

When a gummy is swallowed, CBD enters the gastrointestinal (GI) tract, where it is absorbed primarily in the small intestine. Lipophilic CBD associates with dietary fats and micelles, facilitating uptake across the intestinal epithelium via passive diffusion and possibly carrier‑mediated transport. Once absorbed, CBD travels through the portal vein to the liver, undergoing extensive first‑pass metabolism. Cytochrome P450 enzymes, especially CYP3A4 and CYP2C19, convert CBD to hydroxylated and carboxylated metabolites (e.g., 7‑hydroxy‑CBD, CBD‑COOH). These metabolites can retain biological activity but generally have lower affinity for cannabinoid receptors.

Oral bioavailability of CBD is low, ranging from 6 % to 15 % in human studies. A 2022 crossover trial published in Clinical Pharmacokinetics reported a mean absolute bioavailability of 11 % for a 25 mg oral CBD capsule under fasting conditions, increasing to 17 % when taken with a high‑fat meal. The gummy matrix, which often contains medium‑chain triglyceride (MCT) oil, can modestly improve absorption, though the effect is modest compared with pure oil or sublingual formulations.

Interaction with the Endocannabinoid System

CBD does not bind strongly to CB1 or CB2 receptors-the primary cannabinoid receptors implicated in pain and psychoactive effects. Instead, CBD acts as a "negative allosteric modulator" of CB1, attenuating the receptor's response to Δ9‑tetrahydrocannabinol (THC) and endogenous anandamide. More robust evidence points to CBD's indirect mechanisms:

• Inhibition of FAAH – Fatty acid amide hydrolase (FAAH) degrades anandamide. In vitro studies show CBD can inhibit FAAH, potentially raising anandamide levels and contributing to anxiolysis.
• Serotonin 5‑HT1A Agonism – CBD exhibits partial agonist activity at 5‑HT1A receptors, offering a plausible pathway for reducing anxiety and improving mood.
• TRPV1 Modulation – Transient receptor potential vanilloid 1 (TRPV1) channels mediate pain and inflammation; CBD can desensitize TRPV1, providing an anti‑nociceptive effect.
• PPARγ Activation – Peroxisome proliferator‑activated receptor gamma (PPARγ) activation influences lipid metabolism and inflammation, a pathway explored in animal models of arthritis.

The relative contribution of each pathway likely varies by dose, individual genetics, and concurrent medications. The pharmacodynamic profile of a 10 mg gummy, common in Encore's core line, may be sufficient to modestly engage 5‑HT1A receptors but unlikely to produce measurable CB1 antagonism.

Clinical Dosing Ranges

The therapeutic window for oral CBD remains incompletely defined. Across the 48 RCTs cited earlier, daily CBD doses spanned 5 mg to 1,200 mg. For anxiety and sleep outcomes in non‑clinical populations, the median effective dose hovered around 25 mg to 50 mg per day, often divided into two doses. In the Journal of Clinical Psychology (2024), a double‑blind study gave participants 30 mg of CBD per day for four weeks and observed a statistically significant reduction in self‑reported sleep latency (average decrease of 15 minutes). However, a parallel trial using 10 mg per day did not achieve significance, suggesting a dose‑response relationship.

Ensemble dosing with gummies offers flexibility: users can consume one or multiple gummies to reach their target daily dose. It is important to note that inter‑individual variability in metabolism can cause plasma concentrations to differ by up to threefold for the same ingested amount, underscoring the need for gradual titration and monitoring.

Emerging Evidence and Limitations

While preclinical work demonstrates anti‑inflammatory and neuroprotective properties of cannabidiol, human data are mixed. A 2025 meta‑analysis of chronic pain trials found a small but statistically significant reduction in pain scores (standardized mean difference = −0.24) for oral CBD doses between 20 mg and 40 mg per day, yet the heterogeneity was high (I² = 72 %). Moreover, many studies suffered from short follow‑up periods (≤12 weeks) and relied on subjective scales rather than objective biomarkers.

In the context of "wellness" rather than disease, the evidence remains "emerging." Regulatory agencies such as the World Health Organization (WHO) note that CBD exhibits a favorable safety profile but caution that robust data supporting specific health claims are lacking. Consequently, any health‑related inference about Encore CBD gummies should be qualified with the phrase "may help" rather than "will improve."

Comparative Context

Source / Form	Absorption & Metabolic Impact	Intake Ranges Studied (Daily)	Main Limitations	Typical Populations Studied
Gummy (e.g., Encore)	Oral, low bioavailability (6‑15 %), first‑pass hepatic metabolism	5 – 30 mg	Variable fat content influences absorption	Healthy adults, mild anxiety
Sublingual oil	Bypasses some first‑pass metabolism, moderate bioavailability (~20 %)	10 – 50 mg	Requires precise placement, taste issues	Chronic pain, sleep disorders
Vaporized (inhalation)	Near‑rapid pulmonary absorption, high bioavailability (~30 %)	5 – 25 mg	Respiratory irritation, regulatory constraints	Epilepsy, severe neuropathic pain
Whole‑plant edibles	Mixed cannabinoids, synergistic "entourage effect," low‑moderate bioavailability	10 – 100 mg (total THC+CBD)	THC content may cause psychoactive effects	Cancer‑related symptom management
Dietary sources (hemp seeds)	Negligible CBD, high omega‑3/6 ratio, no pharmacologic effect	N/A	Not a therapeutic CBD source	General nutrition

Population Trade‑offs

H3 – Adults Seeking Mild Stress Relief
For individuals like Jane who experience occasional stress without a diagnosed anxiety disorder, low‑dose gummies (5 – 10 mg) may provide a convenient way to explore potential serotonergic effects. The modest dosing reduces risk of side effects and aligns with the lower end of studied ranges.

H3 – Older Adults with Sleep Fragmentation
Older adults often report disrupted sleep architecture. Studies using 25 – 50 mg oral CBD (including gummy formats) have shown reductions in night‑time awakenings, possibly via 5‑HT1A and PPARγ pathways. However, age‑related reductions in hepatic enzyme activity can elevate plasma CBD levels, warranting cautious titration.

H3 – People on Polypharmacy
CBD inhibits CYP2C19 and CYP3A4, enzymes that metabolize many prescription drugs (e.g., warfarin, certain antiepileptics). For patients on multiple medications, sublingual oil-which bypasses part of the first‑pass effect-might lessen interaction potential, but professional guidance remains essential regardless of formulation.

Safety

Common Side Effects

Clinical trials report that the most frequent adverse events for oral CBD are mild and transient: dry mouth, drowsiness, nausea, and changes in appetite. Incidence rates range from 5 % to 15 % depending on dose and study duration. No serious cardiovascular, hepatic, or neuropsychiatric events have been consistently linked to doses ≤100 mg per day in healthy volunteers.

Populations Requiring Caution

• Pregnant or Breastfeeding Individuals – Limited animal data suggest potential effects on fetal development; human data are insufficient. Most health authorities advise avoidance.
• Children – While FDA‑approved CBD (Epidiolex) is prescribed for specific seizure disorders, over‑the‑counter gummies lack pediatric dosing guidance and should not be used without pediatric specialist input.
• Individuals with Liver Disease – CBD can elevate liver transaminases at higher doses (≥300 mg/day). Even lower doses may require periodic liver function monitoring in patients with pre‑existing hepatic impairment.

Drug Interactions

CBD's inhibition of CYP enzymes can increase plasma concentrations of co‑administered drugs metabolized by the same pathways. Notable examples include:

• Anticoagulants (e.g., warfarin) – Potential for increased INR, requiring dose adjustment.
• Antiepileptics (e.g., clobazam) – Enhanced sedation or seizure threshold alterations.
• Statins – Possible risk of myopathy due to higher statin levels.

Patients should disclose CBD use to their prescriber, especially when using multiple dosing forms (e.g., gummies plus oil).

Frequently Asked Questions

1. Can CBD gummies improve sleep quality?
Limited clinical evidence suggests that oral CBD doses of 20 – 50 mg may modestly reduce sleep latency and increase total sleep time in adults with self‑reported insomnia. The effect appears dose‑dependent and is not observed consistently at doses ≤10 mg. Individual response varies, and gummies also contain sugar or other additives that could influence sleep if consumed too close to bedtime.

2. How long does it take for a gummy to work?
Because gummies are digested, peak plasma CBD concentrations typically occur 2–4 hours after ingestion. Users may notice subtle calming effects earlier, but measurable pharmacologic activity aligns with the absorption timeline. Consistent daily use may lead to cumulative steady‑state levels after about 5–7 days.

3. Are there differences between full‑spectrum and broad‑spectrum CBD in gummies?
Full‑spectrum products contain trace amounts of THC (≤0.3 % by dry weight) alongside other cannabinoids, potentially offering an "entourage effect." Broad‑spectrum removes THC while retaining other cannabinoids. Current human data do not conclusively show superior efficacy for one over the other; the main distinction is the legal and drug‑testing considerations.

4. How should I determine the right dosage?
Start with the lowest available dose (often 5 mg) and monitor subjective effects for a week. If desired outcomes are not achieved and no adverse reactions occur, incrementally increase by 5‑10 mg, not exceeding 30 mg per day without professional guidance. Individual metabolism, body weight, and concomitant medications influence optimal dosing.

5. Will CBD gummies show up on drug tests?
Standard employment drug screens target THC metabolites, not CBD. However, full‑spectrum gummies may contain trace THC that could, in rare cases, exceed the 0.2 ng/mL threshold used in some immunoassays. Broad‑spectrum or isolate gummies eliminate this risk, but laboratory variability means certainty cannot be guaranteed.

Disclaimer

This content is for informational purposes only. Always consult a healthcare professional before starting any supplement.